SVB Leerink Says ‘We Were Wrong,’ Slashes Bluebird Bio Price Target
After the FDA placed a clinical hold on Bluebird Bio Inc’s (NASDAQ:BLUE) cerebral adrenoleukodystrophy gene therapy, SVB Leerink downgraded the stock to Market Perform…
Bluebird Bio’s Shares Drop To 52-Week Low After Another Gene Therapy Trial Placed On FDA Hold
Shares for Bluebird Bio Inc (NASDAQ:BLUE) is hovering at a 52-week low after the FDA placed a clinical hold on clinical…
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.
bluebird bio Q2 EPS $(3.43) Misses $(3.19) Estimate, Sales $7.47M Miss $19.68M Estimate
bluebird bio (NASDAQ:BLUE) reported quarterly losses of $(3.43) per share which missed the analyst consensus estimate of $(3.19) by 7.52 percent. This is a 852.78 percent decrease over losses of $(0.36) per share from
Recap: bluebird bio Q2 Earnings
Shares of bluebird bio (NASDAQ:BLUE) moved higher by 0.9% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 852.78% year over year to ($3.43), which missed the estimate of ($3.19).
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.